Variables

Global (n=37)

Group I (Survivors) (n=31)

Group II (Non-Survivors)  (n=6)

p

 

Clinic and Demographic Age (years), median (IQR) Male gender, No. (%) BMI (Kg/m2), median (IQR) Mean BP (mmHg), median (IQR) HR (/min), median (IQR) HTN, No. (%) Diabetes, No. (%) Ischemic etiology, No. (%) ACEi/ BB/ spironolactone, No. (%) CRT-D or ICD, No. (%) NYHA class (II /III /IV), No. (%)

Blood tests Hemoglobin (g/dL), median (IQR) Creatinine (mg/dL), median (IQR) Sodium (mmol/L), median (IQR) Osmolality (mOsmol/Kg), median (IQR) NT-proBNP (pg/mL), median (IQR) Copeptin (pg/mL), median (IQR)

Echocardiography LV end-diastolic diameter (mm), median (IQR) LV end-diastolic volume (mL), median (IQR) Simpson EF (%),median (IQR) septal E/E’ , median (IQR) E-septum (mm), median (IQR) Shortening fraction (%),median (IQR) dP/dT (mmHg/s), median (IQR) RWT, median (IQR) Ventricular Mass Index (g/m2), median (IQR)

 

72.0 (62.5-75.0) 29 (78) 26.0 (23.7-29.3) 90.0 (80.3-102.0) 76.5 (70-84.3) 29 (78) 11 (30) 15 (41) 35 (95)/ 16 (43)/ 21 (57) 4 (11) 19 (51)/ 12 (33)/ 6 (16)

 

12.8 (12.1-14.0) 1.1 (1.0-1.4) 140.0 (137.5-142.0) 288.0 (282.0-296.0) 2951.0 (1226.8-7801.0) 36.9 (26.5-72.1)

 

64.0 (58.5-71.5) 159.0 (128.5-198.0) 31.5 (25.3-33.6) 16.7 (12.3-23.6) 18.0 (16.0-24.0) 17.5 (12.7-21.1) 591.5 (514.0-715.0) 0.32 (0.27-0.35) 149.1 (123.9-176.3)

 

71.0 (62.0-75.0) 23 (74) 26.0 (23.7-29.1) 91.0 (82.5-102.8) 73.0 (69.3-84.8) 23 (74) 8 (26) 11 (35) 28 (90)/ 14 (45)/ 18 (58) 4 (13) 18 (58)/ 10 (32)/ 3 (10)

 

13.1 (12.3-14.0) 1.1 (0.9-1.3) 140.0 (138.0-142.0) 287.0 (279.0-293.0) 1959.5 (1143.3-6445.3) 33.4 (24.1-48.4)

 

64.0 (58.0-72.0) 155.0 (124.5-193.0) 31.8 (27.3-33.8) 14.8 (11.6-24.1) 18.0 (15.5-23.5) 18.5 (13.6-21.1) 604.0 (495.0-719.0) 0.32 (0.28-0.35) 149.1 (123.1-188.1)

 

73.0 (71.0-76.0) 6 (100) 25.2 (22.4-30.7) 86.0 (78.0-97.0) 79.0 (76.5-88.5) 6 (100) 3 (50) 4 (67) 6 (100)/ 2 (33)/ 3 (50) 0 (0) 1 (17)/ 2 (33)/ 3 (50)

 

12.5 (11.1-13.2) 1.4 (1.0-2.2) 137.5 (134.3-143.8) 297.0 (291.3-309.3) 9341.5 (6464.3-15210.8) 74.6 (55.0-162.4)

 

65.0 (61.8-69.8) 174.5 (112.5-210.5) 26.8 (18.0-32.8) 20.1 (17.9-22.4) 21.0 (17.5-26.3) 16.2 (8.9-25.6) 581.5 (444.5-693.5) 0.27 (0.25-0.33) 151.9 (123.4-166.8)

 

0.302 0.160 0.837 0.198 0.213 0.160 0.235 0.154 0.427/ 0.592/ 0.715 0.351 0.035*

 

0.187 0.129 0.442 0.027* 0.012* 0.002*

 

0.533 0.680 0.187 0.149 0.211 0.967 0.596 0.209 0.742

*significant; ACEi- angiotensin converter enzyme inhibitors; BB- beta-blockers; BMI- body mass index; BP- blood pressure; CRT-D- cardiac resynchronization therapy defibrillator; EF- ejection fraction; HR- heart rate; HTN- hypertension; ICD- implantable cardiac defibrillator; LV- left ventricular; RWT- relative wall thickness
Table 1: Baseline clinical, laboratorial and echocardiographic characteristics and comparison of Survivors vs Non-Survivors